MedPath

Ceftobiprole medocaril

Generic Name
Ceftobiprole medocaril
Brand Names
Zevtera
Drug Type
Small Molecule
Chemical Formula
C26H26N8O11S2
CAS Number
376653-43-9
Unique Ingredient Identifier
YXV28V1B07
Background

Ceftobiprole medocaril is a ceftobiprole prodrug.

Associated Conditions
Pneumonia
Clinical Trials
Related News

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Phase 3
Completed
Conditions
Neonatal Sepsis
Interventions
First Posted Date
2023-05-12
Last Posted Date
2024-12-20
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
9
Registration Number
NCT05856227
Locations
🇧🇬

"Acibadem City Clinic University Hospital Tokuda" EAD, Neonatology Department, Sofia, Bulgaria

🇪🇪

Tallinn Childrens' Hospital, Tallinn, Estonia

🇺🇸

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 11 locations

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Completed
Conditions
Renal Insufficiency
Hepatic Insufficiency
Immunosuppression
Interventions
First Posted Date
2019-11-20
Last Posted Date
2023-07-07
Lead Sponsor
Advanz Pharma
Target Recruit Count
428
Registration Number
NCT04170309
Locations
🇮🇹

Ospedale Sant'Orsola Malpighi, Bologna, Italy

🇪🇸

Hospital Universitari MútuaTerrassa Planta 15, Barcelona, Spain

🇪🇸

Hospital La Moraleja, Madrid, Spain

and more 15 locations

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Phase 3
Completed
Conditions
Community-acquired Pneumonia (CAP)
Hospital-acquired Pneumonia (HAP)
Interventions
Drug: IV standard-of-care cephalosporin
First Posted Date
2018-02-20
Last Posted Date
2023-05-12
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
138
Registration Number
NCT03439124
Locations
🇭🇺

Bekes County Central Hospital, Gyula, Hungary

🇷🇴

Sf. Maria" Children's Emergency Clinical Hospital, IaÅŸi, Romania

🇭🇺

Fejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary

and more 16 locations

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

Phase 2
Completed
Conditions
Inflamed Meninges
Ventriculitis
Suspected Meningitis
First Posted Date
2017-10-23
Last Posted Date
2020-09-16
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
5
Registration Number
NCT03317093
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Phase 3
Completed
Conditions
Staphylococcus Aureus Bacteremia
Interventions
First Posted Date
2017-05-03
Last Posted Date
2023-11-08
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
390
Registration Number
NCT03138733
Locations
🇺🇸

Remington Davis Inc., Columbus, Ohio, United States

🇮🇹

Giuliano Isontina University Health Authority, Trieste, Italy

🇮🇱

The Baruch Padeh Medical Center, Poriyya 'Illit, Israel

and more 57 locations

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Phase 3
Completed
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Drug: vancomycin+aztreonam
First Posted Date
2017-05-02
Last Posted Date
2023-05-12
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
679
Registration Number
NCT03137173
Locations
🇺🇸

Physician Alliance Research Center, Anaheim, California, United States

🇺🇸

Central Valley Research LLC, Fresno, California, United States

🇺🇸

L&C Professional Medical Research Institute, Miami, Florida, United States

and more 29 locations

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Phase 1
Terminated
Conditions
Bacterial Infections
Interventions
First Posted Date
2015-08-19
Last Posted Date
2023-06-05
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
15
Registration Number
NCT02527681
Locations
🇱🇹

Vilnius University Children's Hospital, Vilnius, Lithuania

🇱🇻

Children Clinical University Hospital, Riga, Latvia

🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

and more 11 locations

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Phase 3
Terminated
Conditions
Fever
Neutropenia
Gram-positive Bacterial Infections
Pseudomonas Infection
Interventions
First Posted Date
2007-09-14
Last Posted Date
2012-08-01
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
2
Registration Number
NCT00529282

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

Phase 2
Withdrawn
Conditions
Bacteremia
First Posted Date
2007-07-23
Last Posted Date
2013-02-20
Lead Sponsor
Basilea Pharmaceutica
Registration Number
NCT00505258

Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

Phase 3
Completed
Conditions
Pneumonia
Interventions
First Posted Date
2006-05-16
Last Posted Date
2012-08-02
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
638
Registration Number
NCT00326287
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy